SAR302503

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

MyelofibrosisEssential Thrombocythemia

139 competitors in Myelofibrosis

#DrugCompanyPhaseTrials

1

Ojjaara

GGlaxo Dba Glaxosmithkline

Phase 3

62

Vonjo

OOrsoBio, Inc

Phase 3

43

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

34

Rytelo

GGeron Corporation

Phase 3

35

Best Available Therapy

Novartis

Phase 3

66

Pomalyst

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

27

Navitoclax

AbbVie

Phase 3

58

Fludara

Sanofi

Phase 2

59

Cellcept

Roche

Phase 2

510

Fludara

Sanofi

Phase 2

4Show 48 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Myelofibrosis4 trials

Phase 2 Study of SAR302503 in Patients With Myelofibrosis

Completed·Bristol-Myers Squibb·Phase 2·NCT01420770·30 enrolled

Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis

Completed·Bristol-Myers Squibb·Phase 3·NCT01437787·289 enrolled

Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib

Completed·Bristol-Myers Squibb·Phase 2·NCT01523171·97 enrolled

Show 1 more trial

A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis

Completed·Bristol-Myers Squibb·Phase 1/2·NCT00724334·42 enrolled

Essential Thrombocythemia2 trials

Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly

Completed·Bristol-Myers Squibb·Phase 2·NCT01692366·8 enrolled

Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia

Completed·Bristol-Myers Squibb·Phase 2·NCT01420783·81 enrolled

Renal Impairment1 trial

Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment

Completed·Bristol-Myers Squibb·Phase 1·NCT01763190·36 enrolled

Solid Tumor1 trial

Drug Interaction Study of SAR302503 in Patients With Solid Tumor

Completed·Bristol-Myers Squibb·Phase 1·NCT01585623·16 enrolled

Hepatic Impairment1 trial

Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment

Completed·Bristol-Myers Squibb·Phase 1·NCT01762462·17 enrolled

1 more indication

Patients With Solid Tumors1 trial

Effect of SAR302503 on ECG Activity in Patients With Solid Tumors

Completed·Bristol-Myers Squibb·Phase 1·NCT01836705·60 enrolled

Details

Drug Info

Related News